{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:23:00Z","timestamp":1792120980772,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001605","name":"Epilepsy Foundation","doi-asserted-by":"publisher","award":["Epilepsy Therapy Project"],"award-info":[{"award-number":["Epilepsy Therapy Project"]}],"id":[{"id":"10.13039\/100001605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40263-018-0589-2","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T07:14:57Z","timestamp":1542698097000},"page":"47-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US"],"prefix":"10.1007","volume":"33","author":[{"given":"Tristan T.","family":"Sands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahryar","family":"Rahdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Caminha Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Tilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Roberta","family":"Cilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"issue":"6","key":"589_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791\u2013802. \n                    https:\/\/doi.org\/10.1111\/epi.12631\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"3","key":"589_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(15)00379-8\n                    \n                  .","journal-title":"Lancet Neurol."},{"issue":"21","key":"589_CR3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611618\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"10125","key":"589_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3\n                    \n                  .","journal-title":"Lancet"},{"issue":"8","key":"589_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","volume":"59","author":"JP Szaflarski","year":"2018","unstructured":"Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8):1540\u20138. \n                    https:\/\/doi.org\/10.1111\/epi.14477\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"8","key":"589_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","volume":"47","author":"W Loscher","year":"2006","unstructured":"Loscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia. 2006;47(8):1253\u201384. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2006.00607.x\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"3","key":"589_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.24470","volume":"78","author":"DM Goldenholz","year":"2015","unstructured":"Goldenholz DM, Moss R, Scott J, Auh S, Theodore WH. Confusing placebo effect with natural history in epilepsy: a big data approach. Ann Neurol. 2015;78(3):329\u201336. \n                    https:\/\/doi.org\/10.1002\/ana.24470\n                    \n                  .","journal-title":"Ann Neurol"},{"issue":"10","key":"589_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617\u201324. \n                    https:\/\/doi.org\/10.1111\/epi.13499\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"1\u20132","key":"589_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yebeh.2010.04.001","volume":"18","author":"E Ben-Menachem","year":"2010","unstructured":"Ben-Menachem E, Sander JW, Privitera M, Gilliam F. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav. 2010;18(1\u20132):24\u201330. \n                    https:\/\/doi.org\/10.1016\/j.yebeh.2010.04.001\n                    \n                  .","journal-title":"Epilepsy Behav"},{"issue":"1","key":"589_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/epi.13617","volume":"58","author":"L Treat","year":"2017","unstructured":"Treat L, Chapman KE, Colborn KL, Knupp KG. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58(1):123\u20137. \n                    https:\/\/doi.org\/10.1111\/epi.13617\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"12","key":"589_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1499-1654.2000.001592.x","volume":"41","author":"SD Lhatoo","year":"2000","unstructured":"Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia. 2000;41(12):1592\u20136.","journal-title":"Epilepsia."},{"issue":"Suppl. 10","key":"589_CR12","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1528-1157.1999.tb00886.x","volume":"40","author":"ES Krishnamoorthy","year":"1999","unstructured":"Krishnamoorthy ES, Trimble MR. Forced normalization: clinical and therapeutic relevance. Epilepsia. 1999;40(Suppl. 10):S57\u201364.","journal-title":"Epilepsia."},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.pediatrneurol.2017.02.007","volume":"70","author":"Y Kawakami","year":"2017","unstructured":"Kawakami Y, Itoh Y. Forced normalization: antagonism between epilepsy and psychosis. Pediatr Neurol. 2017;70:16\u20139. \n                    https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.02.007\n                    \n                  .","journal-title":"Pediatr Neurol"},{"issue":"4","key":"589_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1684\/epd.2008.0229","volume":"10","author":"G Gobbi","year":"2008","unstructured":"Gobbi G, Giovannini S, Boni A, Visconti P, Beghi M, Cornaggia CM. Catatonic psychosis related to forced normalization in a girl with Dravet\u2019s syndrome. Epileptic Disord. 2008;10(4):325\u20139. \n                    https:\/\/doi.org\/10.1684\/epd.2008.0229\n                    \n                  .","journal-title":"Epileptic Disord."},{"issue":"8","key":"589_CR15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351. \n                    https:\/\/doi.org\/10.1111\/epi.13060\n                    \n                  .","journal-title":"Epilepsia."},{"issue":"9","key":"589_CR16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, Program UC. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586\u201392. \n                    https:\/\/doi.org\/10.1111\/epi.13852\n                    \n                  .","journal-title":"Epilepsia."},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","volume":"45","author":"CA Press","year":"2015","unstructured":"Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49\u201352. \n                    https:\/\/doi.org\/10.1016\/j.yebeh.2015.02.043\n                    \n                  .","journal-title":"Epilepsy Behav"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0589-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0589-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:26:30Z","timestamp":1574191590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0589-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0589-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"20 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was provided for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maria Roberta Cilio received support from the Epilepsy Therapy Project from the Epilepsy Foundation and has received research funding, paid to her institution, from Insys Therapeutics for a company-sponsored trial. She has also received fees and travel support for serving on a scientific advisory board from Bio-Marin Pharmaceuticals. Michael S. Oldham is currently affiliated with Medpace, Cincinnati, OH, USA. Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, and Nicole Tilton have no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Human Research Ethics Committee of the UCSF Benioff Children\u2019s Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Parents provided written informed consent, and patients provided assent according to their physical and mental capability.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}